{"id":493,"date":"2020-08-29T08:59:50","date_gmt":"2020-08-29T08:59:50","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=493"},"modified":"2020-08-29T09:05:54","modified_gmt":"2020-08-29T09:05:54","slug":"28-aug-2020-ruxolinitib-after-48-h-of-ruxolitinib-treatment-16-18-patients-showed-evident-clinical-improvement","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/28-aug-2020-ruxolinitib-after-48-h-of-ruxolitinib-treatment-16-18-patients-showed-evident-clinical-improvement\/","title":{"rendered":"(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16\/18 patients showed evident clinical improvement"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol<\/p>\n<p>https:\/\/doi.org\/10.3389\/fmed.2020.00466<\/p>\n<p class=\"\">Data collection shows a rapid clinical response with no evolution from <i>non-invasive ventilation<\/i>&nbsp;to mechanical ventilation in 16\/18 patients and no response in two patients (overall response rate\u2014ORR 89%). Already after 48 h of ruxolitinib treatment 16\/18 patients showed evident clinical improvement, and after 7 days of treatment 11\/18 patients showed fully recovered respiratory function (pO<sub>2<\/sub>&nbsp;&gt; 98% in spontaneous breathing), 4\/18 patients had minimal oxygen requirement (2\u20134 L\/m), 1\/18 patient showed stable disease, and 2\/18 patient showed progressive disease. After 14 days, 16\/18 patients showed complete recovery of respiratory function (ORR 89%). Compliance to ruxolitinib planned treatment was 100% and no serious adverse event was recorded. In our case series of 18 critically ill patients with COVID-19 and ARDS, administration of ruxolitinib resulted in a clinical improvement that concurred to modify the standard course of disease. Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS. RESPIRE Study (<strong>R<\/strong>uxolitinib for the treatment of acute r<strong>ESPI<\/strong>ratory dist<strong>RE<\/strong>ss syndrome,&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/a>&nbsp;Identifier: NCT04361903).<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol https:\/\/doi.org\/10.3389\/fmed.2020.00466 Data collection shows a rapid clinical response with no evolution from non-invasive ventilation&nbsp;to mechanical ventilation in 16\/18 patients and no response in&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/28-aug-2020-ruxolinitib-after-48-h-of-ruxolitinib-treatment-16-18-patients-showed-evident-clinical-improvement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16\/18 patients showed evident clinical improvement&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,66],"tags":[67],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/493"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=493"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/493\/revisions"}],"predecessor-version":[{"id":494,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/493\/revisions\/494"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}